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Identification of ligands that interact with nuclear receptors is both a major biological problem and an important
initial step in drug discovery. Several in vitro and in vivo techniques are commonly used to screen ligand
candidates against nuclear receptors; however, none of the current assays allow screening without modification
of either the protein and/or the ligand in a high-throughput fashion. Differential scanning fluorimetry (DSF)
allows unmodified potential ligands to be screened as 10µL reactions in 96-well format against partially purified
protein, revealing specific interactors. As a proof of principle, we used a commercially-available nuclear
receptor ligand candidate chemical library to identify interactors of the human estrogen receptor α ligand
binding domain (ERα LBD). Compounds that interact specifically with ERα LBD stabilize the protein and result
in an elevation of the thermal denaturation point, as monitored by the environmentally-sensitive dye SYPRO
orange.We successfully identified all three compounds in the library that have previously been identified to
interact with ERα, with no false positive results.
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Introduction
Nuclear receptors (NRs) are transcription factors found
in all metazoa that regulate a wide variety of cellular,
physiological and developmental processes. Canonically,
the activities of NRs are modulated by interactions
between small-molecule ligands and a
structurally-conserved ligand-binding domain (LBD) of
the NR, inducing conformational changes that result in
new interaction surfaces for the recruitment of
transcriptional coactivators and/or corepressors (reviewed
by [Glass and Rosenfeld, 2000]).The intrinsic chemical
properties of known NR ligands, in particular, with most
possessing the ability to diffuse readily through both
aqueous and membranous environments, make them
highly effective intercellular signaling molecules
[Mangelsdorf et al., 1995].
Identification of ligands that bind to NRs has become an
important focus of research efforts driven by two
overlapping agendas. First, is the interest in identifying
the “natural” ligand(s) of a given NR to understand the
role of the NR within the organism, especially when the
NR has no known ligand (i.e., “de-orphanization”).
Second, is the perspective of the NR as a target for
pharmaceutical intervention.The desire to identify
interacting partners of NRs has led to a proliferation of
different techniques, each with associated advantages
and disadvantages (reviewed by [Mukherjee and Mani,
2010; Raucy and Lasker, 2010; Schulman and Heyman,
2004; Shi, 2006]).
Differential scanning techniques allow identification of
conditions that enhance the stability of proteins.The
transition from native to denatured protein is measured
as a function of increasing temperature, using either light
scattering (Differential Scanning Light Scattering) or the
fluorescence of an environmentally-sensitive dye
(Differential Scanning Fluorescence – DSF). In plate
format, this allows for a large number of conditions (e.g.,
pH, salt, addition of small molecules) to be assayed
simultaneously. Conditions that cause a protein to shift
to a higher denaturation temperature are identified as
“stabilizing” conditions.Vedadi et al. have pioneered this
technique to determine conditions for an array of proteins
used to optimize conditions for crystal growth [Vedadi et
al., 2006]. Some studies have also used this technique
to demonstrate that peptide or small molecule interactors
have the ability to shift the denaturation point of proteins
to a higher temperature [Qiagen, 2010; Reinking et al.,
2005;Vedadi et al., 2006;Wan et al., 2009]. Here, we
present evidence that suggests this technique
successfully identifies known interactors of the estrogen
receptor α (ERα) from a commercially-available
compound library. Overall, we have found the technique
to be relatively inexpensive and it offers some intriguing
advantages over other commonly-used methodologies.
Reagents and instruments
His6-hERα LDB (302-552) expression vector (kindly
provided by Dino Moras [Eiler et al., 2001]).
Terrific Broth (Fisher Scientific, Waltham, MA).
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EDTA-Free Protease Inhibitor Tablets (Roche,
Indianapolis, IN).
Branson Sonifier 450 (Branson Corporation, Danbury,
CT).
Ni-NTA Superflow (Qiagen, Valencia, CA).
β-estradiol (MP Biomedicals, Solon, OH).
pET15b (EMDBiosciences, San Diego, CA).
Sypro Orange, 5000X (Sigma-Aldrich, St. Louis, MO).
CFX96 Real-Time PCR System (Bio-Rad, Hercules, CA).
Nuclear Receptor Ligand Library BML-2802 (Enzo Life
Sciences, Plymouth Meeting, PA).
Methods
Production and purification of estrogen receptor
BL21 (DE3) E. coli cells were transformed with an
expression vector containing coding information for
His6-hERα LBD (302-552) [Eiler et al., 2001]. Freshly
transformed cells were grown at 37°C in Terrific Broth
until reaching mid-log phase of growth.The culture was
cooled to 15°C and induced with 1mM IPTG overnight
(18 hours). Cells were pelleted at 1800 x g and
resuspended in Binding Buffer (500mM NaCl, 10mM
Imidazole, 5% glycerol @ pH 8.0).Two tablets of
EDTA-free protease inhibitor cocktail were added, and
the cells were lysed by sonication.The lysate was clarified
by centrifugation at 40,000 x g for 30 minutes.The
supernatant was loaded onto 2mL bed volume of nickel
affinity resin in a gravity-flow column, pre-equilibrated
with binding buffer. After allowing the clarified lysate to
flow-through, the column was washed with 400mL of
Binding Buffer. Purified ERα LBD was eluted with elution
buffer (500mM NaCl, 30mM Imidazole, 5% glycerol @
pH 8.0) and dialyzed into Analysis Buffer (500mM NaCl,
50mM HEPES, 5% glycerol, 10mM DTT @ pH 7.5).
“Empty Vector” protein product was produced as above,
except pET15b with no insert was used.
Protein “melting” curves
The RT-PCR machine was programmed to equilibrate
samples at 25°C for 5 minutes and then increase
temperature to 95°C at a rate of 1°C/minute, taking a
fluorescence reading every 0.2°C using a LED/photodiode
set matched to the excitation and emission wavelengths
of SYPRO orange.The melting point of the protein was
obtained as the lowest point of first derivative plot, as
calculated by the software included with the RT-PCR
machine.
Optimal concentrations of ERα LBD and SYPRO orange
dye were determined by performing DSF on a grid of
varying concentrations of protein and SYPRO orange in
Analysis Buffer. For ERα, the optimal conditions were ~1
mg/mL protein (as determined by Bradford Assay) in
Analysis Buffer and 2X SYPRO orange (diluted from
5000X concentrate) within the reaction well, as
determined by maximum range of relative Fluorescence
Units observed in the “melt curve”.
In a single well of a 96-well pCR plate, a 10µL reaction
was conducted by combining 6µL of protein solution (in
Analysis Buffer), 2µL of 10X Sypro orange (diluted from
5000X stock in DMSO with Analysis Buffer) and 2µL of
solution containing either 1mM ligand (diluted from 10mM
DMSO stock with Analysis Buffer) or 10% DMSO (v/v) in
Analysis Buffer (as vehicle controls).The final conditions
in the experimental well were 2X Sypro orange, 200µM
compound (if any), protein concentration ranging from
08-1.2 mg/mL (depending on preparation) and 2% (v/v)
DMSO in Analysis Buffer.
Ligand titrations
A series of Estradiol (E2) dilutions was created in 10%
(v/v) DMS on Analysis Buffer ranging from 1 to 500µM.
Purified ERα LBD was assayed against the E2 dilution
series at two different protein concentrations by combining
either [6µL protein + 2µL ligand solution + 2µL 10X
SYPRO orange] or [3µL protein + 3µL Analysis Buffer +
2µL ligand solution + 2µL 10X SYPRO orange]. DSF was
performed to determine melting points.This process was
repeated for estrone (E1) and tamoxifen citrate.
Results
Upon purification by a single affinity column, the
purification product containing human ERα LBD produced
a denaturation curve with a melting point (Tm) of ~41°C
(representative curve in Figure 1a-b). Addition of
β-estradiol (E2) produced a denaturation curve with two
transitions, at ~41°C and ~59°C (Figure 1c-d).The
presence of two peaks is unlikely to be caused by the
presence of bound and unbound populations of ERα,
since E2 was present at a concentration well above the
dissociation constant of ERα/E2 and in molecular excess
to ERα. Additionally, titration of higher concentrations of
E2 did not alter the magnitude or presence of 41°C
transition (data not shown).The 41°C Tm that remains in
the ERα + E2 in vitro samples is therefore likely to be
caused by non-ERα protein contaminants, as can be
observed in the SDS-PAGE analysis of apo ERα (Figure
2). A mock purification of the bacteria transformed with
an expression vector with no coding DNA inserted in the
multiple cloning site results in purification of several
endogenous bacterial proteins that closely match the
contaminants seen in the ERα purification (Figure 2).
When the denaturation experiment is run on the products
of the “empty vector” purification, the resultant curve
displays a melting curve that closely matches the melting
point seen for apo ERα LBD and the first peak of ERα
LBD plus E2 (Figure 1e-f), but does not change upon
addition of E2.These results indicate that the co-purified
proteins associated with the partial purification of ERα
LBD have a collective melting point of ~41°C. Apo ERα
LBD either also denatures at this range, or does not
display a signal that is otherwise discernable from the
contaminants. However, upon addition of E2, an easily
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significantly higher temperature, indicating the presence
of a specific ERα/E2 complex.
Figure 1.  Using DSF to determine “melting” points of protein
preparations. Representative DSF output from the RT-PCR machine
as matched sets of graphs displaying Relative Fluorescence Units (RFU)
vs. temperature and the first derivative of RFU vs. temperature for ERα
(a-b), ERα plus 200µM E2 (c-d) , and “empty vector” protein (e-f).Tm is
calculated from the first derivative plots on the right.
Figure 2. “Dirty” protein preparations. SDS-PAGE analysis of
“empty” pET 15 vector (EV) and ERα LBD (ER).
Differential scanning fluorimetry was used in a
high-throughput fashion to screen a
commercially-available compound library containing 76
known or suspected nuclear receptor ligands
(Supplementary File 1).The 96-well format of the RT-PCR
machine allowed all compounds to be tested
simultaneously, as well as the addition of four wells
containing vehicle solution as a baseline.When screened
against the “empty vector” protein purification, most wells
displayed melting points similar to the vehicle wells
(Figure 3a). Nonspecific interactions can lead to a
decrease in melting point seen for some compounds.
None of the compounds resulted in higher melting points
for the “empty vector” proteins.When ERα LBD was
screened against the library, three compounds displayed
significant secondary melting points well above that
observed for the vehicle (Figure 3b, Figure 4a-b). All three
compounds are known ERα agonists (β-estradiol, estrone)
or antagonists (tamoxifen citrate).These compounds
induced no secondary melting points in the “empty vector”
protein sample (Figure 4c-d).
Figure 3.  Using DSF to screen a compound library. Maximum melt
temperature (Tmax) recorded for chemical compound library (200µM
ligand concentration) with either empty vector protein preparation (a) or
ERα LBD (b).When multiple Tm are present in a sample, only the higher
value is plotted. Error bars in (b) represent the average of seven replicate
data sets ± Standard Error of the Mean (SEM).
Figure 4. “Hits” from the compound library. Representative DSF
output of wells containing E2 (purple), estrone (red) and tamoxifen citrate
(blue) for screens containing ERα LBD (a-b) or empty vector protein
preparation (c-d).
Titrations of the E2 (Figure 5a) yielded an apparent EC50
that is well above the sub-nanomolar reported values for
ER/E2 associations. Detection limit of this assay is
correlated to the protein concentration (higher protein
concentration yields a higher apparent EC50), which is
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of the DSF experiment.The apparent EC50 of the other
lower affinity “hits” from the screen were also determined
(Figure 5b). Both ligands demonstrated similar protein
concentration - EC50 correlations (data not shown).When
viewed over a broader ligand concentration range (Figure
5b), all three ligands are detected at 10µM, but also
demonstrate subtle increases of the maximum Tm at
higher concentrations of ligand.
Figure 5.  Ligand titrations. a) Titrations of E2 against ER at “high”
(6µL protein in 10µL reaction well, blue trace) and “low” (3µL of protein
in 10µL reaction well, black trace) concentrations, demonstrating that the
apparent EC50 is dependent on protein concentration. b) Titrations of
three “hits” of the screen, E2 (blue trace), E1 (red trace) and tamoxifen
citrate (green trace) against “high” concentration of ER (6µL protein in
10µL reaction well).
Discussion
NR LBDs are generally difficult to purify and concentrate
in the absence of a ligand, but are more tractable when
the ligand is combined with the protein. Many crystal
structures of liganded NR LBDs are produced by
introducing the ligand into the heterologous expression
system prior to overexpression [Hassell et al., 2007].The
relative poor behavior (from the perspective of the purifier)
of apo NR LBDs can be accounted for by a high degree
of conformational mobility which is alleviated upon
introduction of the ligand [Hamuro et al., 2006; Johnson
et al., 2000;Yan et al., 2004]. Accordingly, the ERα LBD
has been reported to be easier to purify to homogeneity
and concentrate when purified in the presence of a ligand
[Eiler et al., 2001; Pike, 2009]. In this assay, we also
demonstrate that upon ligation, the stabilization of ERα
LBD can be easily measured using differential scanning
fluorimetry.
Herein, we demonstrate DSF has the ability to identify all
known interactors of ERα contained in a
commercially-available compound library with a high
degree of reproducibility and minimal-to-no background
in a 96-well plate format using 10µL reaction volumes.
We expect the assay should also be able to function with
384-well format versions of RT-PCR machines with the
appropriate channel that are currently available on the
market. Like some other commonly used in vitro ligand
identification assays, DSF requires relatively small
amounts of both ligand and protein and has the ability to
detect (but not differentiate) interactors that can potentially
activate or repress transcription of the genes under the
regulation of the NR. Unlike other in vitro assays, DSF
does not require that either the protein or the ligand need
be tagged (radioactively, fluorescently or with other
adducts). Also, unlike in vivo transactivation or yeast
two-hybrid assays, DSF does require a separate fusion
construct.The same expression construct used to
produce protein for DSF can also be used for other in
vitro investigations such as crystallization trials or other
biophysical characterizations.The detection limit of this
technique appears to be determined by combination of
both the affinity of the protein-ligand interaction, as well
as the concentration of the protein used in the assay.
Lower protein concentration actually improves the
detection limit, but quality of the signal sets a practical
lower limit on how dilute a protein can be used.
For many nuclear receptors, especially among
non-vertebrates, no ligands are known, making it
impossible to incorporate ligands to improve the stability
and behavior of a NR LBD. As we have shown, DSF
tolerates relatively low protein concentration and
preparations that are not completely pure, making it
especially amenable to qualitative identification of ligands
of orphan NRs.We believe this technique has the
potential to be applicable to other NR LBDs than can be
at least partially purified.
Supplementary Material
Supplementary File 1:Nuclear receptor ligands used in
high-throughput screening. Compounds contained within
this library (Enzo) are known ligands for a variety of
nuclear receptors, including hERα.
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